10x Genomics Selects First 45 Members for Visium Clinical Translational Research Network
17 June 2020 - 11:00PM
10x Genomics, Inc. (Nasdaq: TXG) today unveiled the first 45
members selected for participation in its Visium Clinical
Translational Research Network (CTRN). Members selected are focused
on research in oncology, immuno-oncology, neuroscience, infectious
disease, inflammation and fibrosis, COVID-19 and more. The 10x
Genomics Visium CTRN was established to improve and accelerate
workflows related to assessing the spatial cellular relationship in
clinical translational research studies. Visium has the
potential to aid in many clinical translational research
applications, including biomarker and drug target discovery,
engineered immune cell therapy and clinical trial development.
“The technologies powering today’s research have led to
discoveries that would have been unprecedented ten years ago, but
the tools that help translate genomic research to a clinical
setting haven’t always kept pace,” said Michael Schnall-Levin, SVP
R&D and Founding Scientist at 10x Genomics. “By establishing
the Visium Clinical Translational Research Network, we can help
accelerate the clinical translational process by bridging the gap
between scientific discoveries and patient care solutions.”
The first 45 members of 10x Genomics’ Visium CTRN were selected
from 185 total applications and represent a diverse range of
studies that are taking place around the world. The 10x Genomics
CTRN will connect researchers across 39 global institutions,
including:
- Barcelona Supercomputing Center
- Cancer Research Centre of Lyon (CRCL)
- Centre de Recherche des Cordeliers (Inserm, Sorbonne
Université, Université de Paris)
- Duke University
- Garvan Institute of Medical Research
- GSK
- Hospital Italiano Buenos Aires, IMTIB
- Humanitas Research Hospital
- Institut Imagine
- Johns Hopkins Medical Institutions
- Josep Carreras Leukaemia Research Institute
- Lieber Institute for Brain Development
- Ludwig-Maximilians University Munich
- Mass General Cancer Center
- Nanjing Drum Tower Hospital
- Queensland University of Technology
- RIKEN Center for Biosystems Dynamics Research
- RIKEN Center for Integrative Medical Sciences
- Sylvester Comprehensive Cancer Center and Bascom Palmer Eye
Institute, University of Miami Miller School of Medicine
- University of Michigan Rogel Cancer Center
“We are excited to be a part of the collaborative Visium
Clinical Translational Research Network and look forward to
harnessing the power of spatial gene expression,” said Dr. Sophia
Shalhout, Cutaneous Oncology Clinical Research Fellow at Mass
General Cancer Center. “As part of Dr. David M. Miller’s team at
the Mass General Cancer Center, we seek to advance our
understanding of the biomarkers of tumor response and resistance to
therapy in patients with advanced rare skin cancers. Joining this
global research community and working with experts at 10x Genomics
will be essential as we aim to use Visium spatial solutions to
resolve the heterogeneity in the tumor microenvironment of this
rare cohort.”
As members of the Visium CTRN, researchers gain exclusive access
to a collaborative, global research community dedicated to
accelerating clinical translational research workflows, as well as
substantial discounts and specialized support relating to the 10x
Genomics Visium platform. Members will also have the opportunity to
present at the 10x Genomics CTRN Spatial Summit, the details of
which are expected to be revealed later this year.
“Membership in the 10x Genomics CTRN is an important step
forward for my lab, enabling us to pursue the translation of
cellular genomic discoveries into meaningful improvements for
cancer patients,” said Dr. Alexander Swarbrick, Senior Research
Fellow, Garvan Institute of Medical Research.
“We’re really excited to participate in the CTRN, and use Visium
to better characterize spatial patterns of genes dysregulated in
debilitating brain disorders,” added Dr. Andrew E. Jaffe, Lead
Investigator, Lieber Institute for Brain Development.
More information on the Visium Clinical Translational Research
Network and its members can be found by visiting
www.10xgenomics.com/ctrn.
To learn more about 10x Genomics, visit 10xgenomics.com.
About 10x Genomics10x Genomics is a life
science technology company building products to interrogate,
understand and master biology to advance human health. The
company’s integrated solutions include instruments, consumables and
software for analyzing biological systems at a resolution and scale
that matches the complexity of biology. 10x Genomics products have
been adopted by researchers around the world including 97 of the
top 100 global research institutions and 19 of the top 20 global
pharmaceutical companies, and have been cited in over 1,000
research papers on discoveries ranging from oncology to immunology
and neuroscience. The company's patent portfolio comprises more
than 740 issued patents and patent applications.
Forward Looking StatementsThis press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995 as contained in
Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended.
Forward-looking statements generally can be identified by the use
of forward-looking terminology such as “may,” “will,” “should,”
“expect,” “plan,” “anticipate,” “could,” “intend,” “target,”
“project” “contemplate,” “believe,” “estimate,” “predict,”
“potential” or “continue” or the negatives of these terms or
variations of them or similar terminology. These
forward-looking statements include statements regarding 10x
Genomics, Inc.’s partnership activities, which involve risks and
uncertainties that could cause 10x Genomics, Inc.’s actual results
to differ materially from the anticipated results and expectations
expressed in these forward-looking statements. These statements are
based on management’s current expectations, forecasts, beliefs,
assumptions and information currently available to management, and
actual outcomes and results could differ materially from these
statements due to a number of factors. These and additional risks
and uncertainties that could affect 10x Genomics, Inc.’s financial
and operating results and cause actual results to differ materially
from those indicated by the forward-looking statements made in this
press release include those discussed under the captions "Risk
Factors" and "Management's Discussion and Analysis of Financial
Condition and Results of Operations" and elsewhere in the documents
10x Genomics, Inc. files with the Securities and Exchange
Commission from time to time. The forward-looking statements in
this press release are based on information available to 10x
Genomics, Inc. as of the date hereof, and 10x Genomics, Inc.
disclaims any obligation to update any forward-looking statements
provided to reflect any change in its expectations or any change in
events, conditions, or circumstances on which any such statement is
based, except as required by law. These forward-looking statements
should not be relied upon as representing 10x Genomics, Inc.’s
views as of any date subsequent to the date of this press
release.
Disclosure Information10x Genomics uses filings
with the Securities and Exchange Commission, its website
(www.10xgenomics.com), press releases, public conference calls,
public webcasts and its social media accounts as means of
disclosing material non-public information and for complying with
its disclosure obligations under Regulation FD.
ContactsMedia:media@10xgenomics.comInvestors:investors@10xgenomics.com
10x Genomics (NASDAQ:TXG)
Historical Stock Chart
From Apr 2024 to May 2024
10x Genomics (NASDAQ:TXG)
Historical Stock Chart
From May 2023 to May 2024